FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166396322> ?p ?o ?g. }

• W3166396322 endingPage "9033" @default.
• W3166396322 startingPage "9033" @default.
• W3166396322 abstract "9033 Background: The treatment landscape in advanced non-small cell lung cancer (NSCLC) has undergone significant changes, with immune checkpoint inhibitor (ICI) +/- chemotherapy now the preferred first-line (1L) regimen for metastatic, non-mutated NSCLC. However, only limited clinical data are available to guide subsequent treatment selection. Nintedanib (Vargatef), an oral triple angiokinase inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) pathways, is approved in the EU and other countries in combination with docetaxel for the treatment of advanced adenocarcinoma NSCLC after failure on 1L chemotherapy. Methods: This analysis is part of the ongoing, prospective, non-interventional VARGADO study (NCT02392455) of nintedanib + docetaxel. Here, we present initial efficacy and safety results from 100 patients (pts) with adenocarcinoma NSCLC in Cohort C, who received second-line (2L) nintedanib + docetaxel after failure on prior 1L ICI in combination with chemotherapy. Results: In Cohort C, the median age was 63 years (range: 43–84); 58 pts (58.0%) were men, and 71 pts (71.0%) had ECOG PS 0/1. Ninety-five pts (95.0%) had received prior 1L pembrolizumab-based combination therapy. Thirty-nine pts (39.0%) had progressed within 6 months after the start of 1L therapy, and 66 pts (66.0%) had progressed within 9 months. Objective response rate with 2L nintedanib + docetaxel was 37.3% (22/59 pts), disease control rate was 67.8% (40/59 pts), and median progression-free survival (PFS) was 4.4 months (95% confidence interval [CI]: 2.6–6.6). Among pts who had experienced disease progression < 9 months after the start of 1L therapy (n = 66), median PFS from the start of 2L nintedanib + docetaxel was 4.1 months (95% CI: 2.5–6.6). Among pts with disease progression ≥9 months after the start of 1L therapy (n = 34), median PFS from the start of 2L nintedanib + docetaxel was 8.5 months (95% CI: 2.4–not estimable). Grade ≥3 treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs leading to treatment discontinuation were observed in 47 pts (47.0%), 37 pts (37.0%) and 28 pts (28.0%), respectively. Conclusions: Initial data from VARGADO Cohort C provide the first evidence that 2L nintedanib + docetaxel has encouraging and clinically meaningful efficacy, and a manageable safety profile in pts with advanced adenocarcinoma NSCLC following progression on 1L ICI in combination with chemotherapy. Clinical trial information: NCT02392455." @default.
• W3166396322 created "2021-06-22" @default.
• W3166396322 creator A5015898233 @default.
• W3166396322 creator A5024282182 @default.
• W3166396322 creator A5032314001 @default.
• W3166396322 creator A5036078463 @default.
• W3166396322 creator A5040589443 @default.
• W3166396322 creator A5041857102 @default.
• W3166396322 creator A5062659492 @default.
• W3166396322 creator A5067921018 @default.
• W3166396322 creator A5074420045 @default.
• W3166396322 creator A5075710937 @default.
• W3166396322 creator A5082092472 @default.
• W3166396322 creator A5087787245 @default.
• W3166396322 date "2021-05-20" @default.
• W3166396322 modified "2023-10-18" @default.
• W3166396322 title "Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C." @default.
• W3166396322 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.9033" @default.
• W3166396322 hasPublicationYear "2021" @default.
• W3166396322 type Work @default.
• W3166396322 sameAs 3166396322 @default.
• W3166396322 citedByCount "3" @default.
• W3166396322 countsByYear W31663963222021 @default.
• W3166396322 countsByYear W31663963222022 @default.
• W3166396322 crossrefType "journal-article" @default.
• W3166396322 hasAuthorship W3166396322A5015898233 @default.
• W3166396322 hasAuthorship W3166396322A5024282182 @default.
• W3166396322 hasAuthorship W3166396322A5032314001 @default.
• W3166396322 hasAuthorship W3166396322A5036078463 @default.
• W3166396322 hasAuthorship W3166396322A5040589443 @default.
• W3166396322 hasAuthorship W3166396322A5041857102 @default.
• W3166396322 hasAuthorship W3166396322A5062659492 @default.
• W3166396322 hasAuthorship W3166396322A5067921018 @default.
• W3166396322 hasAuthorship W3166396322A5074420045 @default.
• W3166396322 hasAuthorship W3166396322A5075710937 @default.
• W3166396322 hasAuthorship W3166396322A5082092472 @default.
• W3166396322 hasAuthorship W3166396322A5087787245 @default.
• W3166396322 hasConcept C126322002 @default.
• W3166396322 hasConcept C141071460 @default.
• W3166396322 hasConcept C143998085 @default.
• W3166396322 hasConcept C2776256026 @default.
• W3166396322 hasConcept C2776694085 @default.
• W3166396322 hasConcept C2777063308 @default.
• W3166396322 hasConcept C2777714996 @default.
• W3166396322 hasConcept C2778341716 @default.
• W3166396322 hasConcept C2780171596 @default.
• W3166396322 hasConcept C2781190966 @default.
• W3166396322 hasConcept C2781413609 @default.
• W3166396322 hasConcept C71924100 @default.
• W3166396322 hasConceptScore W3166396322C126322002 @default.
• W3166396322 hasConceptScore W3166396322C141071460 @default.
• W3166396322 hasConceptScore W3166396322C143998085 @default.
• W3166396322 hasConceptScore W3166396322C2776256026 @default.
• W3166396322 hasConceptScore W3166396322C2776694085 @default.
• W3166396322 hasConceptScore W3166396322C2777063308 @default.
• W3166396322 hasConceptScore W3166396322C2777714996 @default.
• W3166396322 hasConceptScore W3166396322C2778341716 @default.
• W3166396322 hasConceptScore W3166396322C2780171596 @default.
• W3166396322 hasConceptScore W3166396322C2781190966 @default.
• W3166396322 hasConceptScore W3166396322C2781413609 @default.
• W3166396322 hasConceptScore W3166396322C71924100 @default.
• W3166396322 hasIssue "15_suppl" @default.
• W3166396322 hasLocation W31663963221 @default.
• W3166396322 hasOpenAccess W3166396322 @default.
• W3166396322 hasPrimaryLocation W31663963221 @default.
• W3166396322 hasRelatedWork W1507921223 @default.
• W3166396322 hasRelatedWork W181704052 @default.
• W3166396322 hasRelatedWork W1969868300 @default.
• W3166396322 hasRelatedWork W2158387151 @default.
• W3166396322 hasRelatedWork W2466112259 @default.
• W3166396322 hasRelatedWork W2540150860 @default.
• W3166396322 hasRelatedWork W2592132026 @default.
• W3166396322 hasRelatedWork W2606994187 @default.
• W3166396322 hasRelatedWork W2898286087 @default.
• W3166396322 hasRelatedWork W2999789808 @default.
• W3166396322 hasVolume "39" @default.
• W3166396322 isParatext "false" @default.
• W3166396322 isRetracted "false" @default.
• W3166396322 magId "3166396322" @default.
• W3166396322 workType "article" @default.